BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medicine by Design - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medicine by Design
X-ORIGINAL-URL:https://mbd.ccrm.ca
X-WR-CALDESC:Events for Medicine by Design
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20170312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20171105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20180220T120000
DTEND;TZID=America/Toronto:20180220T130000
DTSTAMP:20260405T184955
CREATED:20180820T161012Z
LAST-MODIFIED:20191126T153223Z
UID:5689-1519128000-1519131600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Princess Imoukhuede\, PhD\, University of Illinois at Urbana-Champaign
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the Ontario Institute for Regenerative Medicine\, is pleased to welcome Princess Imoukhuede\, PhD\, assistant professor of bioengineering at the University of Illinois at Urbana-Champaign. Professor Imoukhuede will deliver a talk on Systems Biology: Recipes for Advancing Predictive Biology. \nDownload event poster \nLive stream talk (link will be live shortly before the event) \nTalk Abstract\nDirected control of angiogenesis can improve the treatment of over 70 diseases. We hypothesize that such control can be reached by computationally integrating two types of parameters: protein concentrations and protein-protein interaction (PPI) kinetics. In support of this hypothesis\, we report three key advancements: (1) engineering of new quantitative fluorescent nanosensors (qFluors) to measure plasma membrane vascular endothelial growth factor receptor (VEGFR) (Fig. 1) and platelet derived growth factor receptor (PDGFR) concentrations and heterogeneity; (2) discovery and measurement of new cross-family interactions between PDGFs and VEGFR2 (Fig. 2); and (3) development of computational models that accurately predict VEGFR-mediated protein phosphorylation\, cell proliferation\, and cell migration (Fig. 3). \nOur approaches are advancing us towards the goal of directing the growth factor receptor signaling that underlies angiogenesis. Firstly\, our qFluors are establishing a new method for quantifying biomarker heterogeneity\, which can be translated to clinical pathology. More immediately\, this approach is providing the receptor concentration data necessary for accurate computational model development. Additionally\, our discovery and measurement of cross-family binding represents a paradigm shift\, where PPI interaction kinetics\, not family\, define our view of protein function. More immediately\, these kinetic measurements provide the necessary data for predicting cell responses. Finally\, our computational models are integrating each of the parameters and providing validated predictions of angiogenic cell response. \nThis material is based upon work supported by the National Science Foundation (NSF)\, American Heart Association (AHA)\, and American Cancer Society (ACS) under Grant #s: NSF CBET: 1512598; NSF CAREER: 1653925; NSF BPE:1648454; AHA:16SDG26940002; and ACS-IL: 282802 \nBiography\nProfessor Imoukhuede earned her SB in Chemical Engineering from the Massachusetts Institute of Technology (MIT) where her research earned her the coveted Class of 1972 award\, presented annually to the project that most improves the quality of life through its impact on people and/or the environment. Professor Imoukhuede’s research was funded by the National Science Foundation’s Biotechnology Process Engineering Center at MIT and through a Bioengineering Undergraduate Research Award by the MIT Division of Bioengineering and Environmental Health.\nProfessor Imoukhuede was honored with the 2002 Betsy Schumaker Award (also known as the MIT female athlete of the year)\, was selected to a COSIDA/VERIZON Academic All-America team\, and was awarded an NCAA postgraduate scholarship. Professor Imoukhuede championed the importance of social responsibility in the midst of academic excellence by serving as the President of the MIT Committee on Multiculturalism\, President of the MIT chapter of the American Institute of Chemical Engineers (AIChE)\, and held both chapter and zone offices in the National Society of Black Engineers (NSBE). \nAfter earning her undergraduate degree\, Professor Imoukhuede pursued graduate study in bioengineering at the California Institute of Technology (Caltech) in Pasadena\, CA. Here\, she combined sensitive techniques in biomedical optics with nanoparticle imaging towards understanding the structure\, function\, and trafficking of a key protein in epilepsy\, the GABA transporter\, GAT1. She also performed research in nicotine addiction through molecular imaging of nicotinic acetylcholine receptors. Professor Imoukhuede’s research in nanotechnology earned her the Kavli Nanoscience Institute Award and her graduate research was supported by the National Institutes of Health (NIDA). Professor Imoukhuede was the first African-American woman to be awarded a Bioengineering PhD by Caltech and was only the second African-American woman to earn a PhD from Caltech’s Division of Engineering and Applied Science. \nProfessor Imoukhuede completed a post-doctoral fellowship in the Biomedical Engineering Department at the Johns Hopkins University School of Medicine.  During her fellowship at Johns Hopkins\, she was 1 of ten post-doctoral fellows nationwide to earn the prestigious United Negro College Fund/Merck Postdoctoral Research Fellowship\, 1 of 6 young investigators to earn the FASEB Postdoctoral Professional Development Award\, and her work was awarded a Poster Award at the biennial Gordon Conference in Angiogenesis. Her post-doctoral work was also supported by the National Institutes of Health (NHLBI).
URL:https://mbd.ccrm.ca/event/global-speaker-series-princess-imoukhuede-february-2018/
LOCATION:Canada
CATEGORIES:Global Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20180116T120000
DTEND;TZID=America/Toronto:20180116T130000
DTSTAMP:20260405T184955
CREATED:20180820T155649Z
LAST-MODIFIED:20191125T194345Z
UID:5683-1516104000-1516107600@mbd.ccrm.ca
SUMMARY:Global Speaker Series: Lee Rubin\, PhD\, Harvard University
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians. \nMedicine by Design\, in partnership with the Ontario Institute for Regenerative Medicine\, is pleased to welcome Lee Rubin\, PhD\, professor in the Department of Stem Cell and Regenerative Biology at Harvard University. This event will be webcast \nBiography\nLee Rubin received his PhD in Neuroscience from The Rockefeller University and completed postdoctoral fellowships in pharmacology at Harvard Medical School and in neurobiology at Stanford University School of Medicine. He has broad experience in both academia and industry\, particularly in the realms of cell-based assays and drug discovery. Prior to Harvard\, he was chief scientific officer of Curis\, Inc.\, a Cambridge-based biotechnology company\, where his group identified the first small molecule regulators of the hedgehog signalling pathway. One of their antagonists was developed by Genentech and is now (as Erivedge) approved as the first oral treatment for metastatic basal cell carcinoma. At Harvard\, much of Rubin’s work is focused on finding key molecular mediators of different neurodegenerative diseases and on searching for effective pre-clinical therapeutic candidates. His group’s research takes advantage of their ability to produce large numbers of patient-derived induced pluripotent stem cell lines and of effective means of deriving large numbers of differentiated neurons from them. They have set up an array of techniques that allow them to identify early cellular and physiological changes in neurons as they become diseased. For example\, they have identified new targets for the treatment of the motor neuron disorders spinal muscular atrophy and amyotrophic lateral sclerosis. They are also studying autism spectrum disorders\, Parkinson’s disease and Alzheimer’s disease. Recently\, his group discovered that a circulating protein\, GDF11\, has the ability to reverse some of the changes in the central nervous system associated with aging. They are actively exploring the therapeutic implications of these observations.
URL:https://mbd.ccrm.ca/event/global-speaker-series-lee-rubin-january-2018/
LOCATION:Canada
CATEGORIES:Global Speaker Series
END:VEVENT
END:VCALENDAR